Equity Overview
Price & Market Data
Price: $3.51
Daily Change: -$0.23 / 6.55%
Daily Range: $3.43 - $4.18
Market Cap: $286,627,680
Daily Volume: 3,869,265
Performance Metrics
1 Week: 74.63%
1 Month: 51.95%
3 Months: 294.4%
6 Months: 263.7%
1 Year: 205.2%
YTD: 312.9%
Company Details
Employees: 32
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.